Grifols | GRFS - Pre Tax Profit


Grifols reported EUR257.85M in Pre-Tax Profit for its fiscal quarter ending in December of 2024.





Pre Tax Profit Change Date
Alaunos Therapeutics USD -7.84M 633K Dec/2023
Arca Biopharma USD -31.82M 2.24M Mar/2026
aTyr Pharma USD -153K 25.59M Mar/2026
Bio Path USD -976K 3.62M Sep/2025
Brainstorm Cell Therapeutics USD -2.11M 797K Sep/2025
Capricor Therapeutics USD -30.17M 5.6M Dec/2025
Cara Therapeutics USD -6.8M 1.9M Mar/2026
GlaxoSmithKline GBP 2.68B 532M Jun/2026
Grifols EUR 257.85M 190.87M Dec/2024
Immunic USD -19.3M 6.28M Dec/2025
Minerva Neurosciences USD 22.51M 30.74M Sep/2024
Nektar Therapeutics USD -43.09M 8.39M Mar/2026
Sangamo BioSciences USD -36.05M 12.94M Jun/2024
TherapeuticsMD USD -1.05M 241K Jun/2024